Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Germany Drug Cost-Benefit Proposal Departs From U.K., Other Approaches

Executive Summary

Advisors to the German government have sketched an approach for evaluating drug costs relative to benefits that could depart significantly from the practices of established institutions like the U.K.'s National Institute for Health and Clinical Excellence
Advertisement

Related Content

Biosimilars Create Class-wide Competition, German Experience Finds
Biosimilars Create Class-wide Competition, German Experience Finds
Sandoz Hones Biosimilars Strategy
U.K. May Turn To “Value-Based” Drug Pricing In Place Of Price Limits
U.K. May Turn To “Value-Based” Drug Pricing In Place Of Price Limits
Advertisement
UsernamePublicRestriction

Register

PS049362

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel